A DNA probe study on the origin of the cancer recognition, immunedefense suppression and serine protease protection peptide.
A quantitative "two DNA probe" dot blot hybridization assay, using chemiluminescence detection, was used to distinguish between the mRNA and DNA coding for the cancer recognition, immunedefense suppression, and serine protease protection (CRISPP) peptide, and the partially homologous C-terminal end sequence of the alpha1-PI. In cancer cells, there is up to 2.4 times more mRNA and up to 6.3 times more DNA coding for the CRISPP peptide than for the homologous alpha1-PI in their normal cell counterparts. This corroborates results of the "two antibody" immunoassay, which showed that cancer cells produce the CRISPP, peptide in addition to alpha1-PI molecules. The amplified transcription of the CRISPP peptide DNA could be the result of derepression and/or translocation of an inherited, or acquired, heritable damage to the DNA in the exon V of the alpha1-PI gene. Expression of the CRISPP peptide mRNA and DNA is SV40 transformed cells could indicate that a viral transduction causes the amplified transcription of a mutated exon V of the alpha1-PI gene and/or loss of a specific suppressor gene. The CRISPP peptide with its multiple, cancer-promoting biological effects may qualify as a product of a novel, as yet unidentified, oncogene. The detection of the CRISPP peptide DNA regions, using the two DNA probe, or some other suitable methods, might be a useful adjunct in cancer diagnosis of biopsies and/or in predictive diagnosis of familial cancers.